Halia Therapeutics Appoints Paul Jones as Chief Strategy Officer

Halia Therapeutics has appointed Paul Jones as its new Chief Strategy Officer and General Manager for International Markets, reinforcing its commitment to developing resilience-based therapies. This announcement comes as part of the company’s strategy to enhance its collaboration with the Department of Health in Abu Dhabi, focusing on leveraging the Emirati Genome dataset to identify genetic resilience factors that can mitigate disease.

In his newly established role, Jones will spearhead the acceleration of GENMOR-AI, Halia’s proprietary platform designed to identify genetic modifiers of disease through artificial intelligence. His extensive experience in genomics and digital health transformation positions him to play a crucial role in advancing Halia’s mission.

According to David Bearss, Ph.D., CEO of Halia Therapeutics, “We are thrilled to welcome Paul to Halia. His proven track record in large-scale genomics initiatives—from the UK’s 100,000 Genomes Project to the Emirati Genome Programme—makes him an exceptional addition to our leadership team.” Bearss emphasized that Jones’s expertise aligns perfectly with Halia’s objective to create transformative medicines based on resilience biology.

Jones brings over 30 years of experience in the life sciences sector, with a focus on genomics, precision medicine, and innovative health solutions. Prior to joining Halia, he served as the CEO of the Omics Centre of Excellence at M42, a global tech-enabled health company in Abu Dhabi, where he played a pivotal role in the Emirati Genome Program. His career also includes significant positions at Illumina and Genomics England, where he contributed to the landmark 100,000 Genomes Project.

Halia’s focus on resilience extends to its APOE4 program, which studies individuals carrying the highest-risk genetic variant for Alzheimer’s disease who never develop the condition. By utilizing GENMOR-AI on extensive genomic datasets, Halia aims to uncover resilience mechanisms that can inform new therapies for various health challenges, including neurodegeneration, metabolic disorders, cardiovascular diseases, and cancer.

“I’m excited to join Halia at this pivotal moment,” Jones remarked. “The company’s unique focus on genetic resilience—rather than just disease risk—represents the next frontier in precision medicine. By combining cutting-edge AI with strategic global partnerships, Halia is positioned to revolutionize drug discovery and patient outcomes.”

Halia Therapeutics, headquartered in Lehi, Utah, is dedicated to treating the root causes of inflammation through innovative biopharmaceutical solutions. The company is actively pursuing global partnerships in clinical research, drug discovery, and personalized medicine, aiming to develop data-driven therapies that enhance both lifespan and quality of life.

For more information about Halia Therapeutics, visit their website at www.haliatx.com or follow them on LinkedIn and Twitter @HaliaTx.

Contact information for media inquiries can be directed to Taylor Avei, Director of Business Development, at [email protected] or by phone at +1 (385) 355-4315.